亿胜生物科技(01061.HK)拟斥不超310万美元认购Antikor股份
格隆汇7月19日丨亿胜生物科技(01061.HK)宣布,为促成集团与Antikor的策略性合作,于2019年7月19日,公司全资附属EssexBioInvestment与(其中包括)Antikor订立认购及股东契据。
根据认购及股东契据,EssexBio-Investment有条件同意最多分五期认购认购股份,总代价最多为310万美元;及将可换股债券的全部本金额35万美元用于部分偿付认购事项,方式为行使可换股债券附带的转换权。
假设全部五批认购股份获EssexBio-Investment悉数认购,则认购股份将相当于Antikor的经扩大全部已发行股本约40.12%(按悉数摊薄基准计算)。在完成各期认购事项之其他条件中,第一期认购事项须待EssexBioInvestment按总代价约30.79万英镑完成销售贷款票据之收购事项及EssexBio-Investment与Antikor订立知识产权特许协议后,方告完成。
作为集团与Antikor的策略业务合作的一部分,Essex Bio-Investment与Antikor将订立知识产权特许协议,据此,Antikor将向EssexBio-Investment授出(其中包括)有关指定专利及技术的独家许可及与其有关或与之相关之知识之独家许可,两者均用於开发、使用、销售或以其他方式供应特许产品、就临床试验申请及取得监管批准,并取得市场推广授权,于各情况下均根据知识产权特许协议之条款用于适用之使用领域及适用地区,并须支付特许权费。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.